肿瘤细胞治疗研究
英文原题：Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response.
72 名参与者的一个亚组接受了 CARTx 后疫苗反应的评估。
体液免疫相关不良事件，包括低丙种球蛋白血症和B细胞耗竭，在血液恶性肿瘤的CAR-T 细胞治疗（CARTx）后带来长期感染风险。这项前瞻性研究评估了分别靶向CD19和CD20（B细胞）或BCMA（浆细胞）的CARTx前及CARTx后长达一年的病原体特异性体液免疫动力学，分别纳入100名和28名个体。针对12种疫苗可预防病原体检测抗体，并使用全面高通量抗体谱分析。对72名参与者的一个亚组评估了CARTx后疫苗应答。在此，我们表明，在靶向CD19、CD20或BCMA的CAR-T细胞治疗（CARTx）后，病原体特异性体液免疫没有显著变化。然而，到CARTx后一年时，在CD19-CARTx和CD20-CARTx受者中，有多达三分之一的常规疫苗可预防病原体缺乏血清保护性抗体；在BCMA-CARTx受者中，有近一半的疫苗可预防病原体缺乏血清保护性抗体。疫苗接种前B细胞计数是疫苗应答的主要预测因素。
Humoral immune-related adverse events, including hypogammaglobulinemia and B cell depletion, pose long-term infection risks after chimeric antigen receptor T cell therapy (CARTx) for hematologic malignancies. This prospective study evaluates the kinetics of pathogen-specific humoral immunity prior to and up to a year after CARTx targeting CD19 and CD20 (B cells) or BCMA (plasma cells) in 100 and 28 individuals, respectively. Antibodies are tested for 12 vaccine-preventable pathogens and using comprehensive high-throughput antibody profiling. A subset of 72 participants are evaluated for post-CARTx vaccine responses. Here, we show pathogen-specific humoral immunity does not significantly change after CD19-, CD20-, or BCMA-targeted CAR-T cell therapy (CARTx). However, seroprotective antibodies are absent for up to one-third of routine vaccine-preventable pathogens in CD19- and CD20-CARTx recipients and for nearly half of vaccine-preventable pathogens in BCMA-CARTx recipients by one-year post-CARTx. Pre-vaccination B cell count is the main predictor of vaccine response.
MEMBER ACCOUNT
登录成功会直接打开下一页。
